Effects of lenvatinib on glucose, cholesterol, triglycerides and estimated cardiovascular risk in patients with advanced thyroid cancer
Endocrine · 2024
DOI: 10.1007/s12020-024-04003-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine, 2024. Verfasst von E Acitelli und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational and Precision Medicine, Sapienza University, Rome, Italy. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Quinolines, Phenylurea Compounds, Triglycerides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Multitarget kinase inhibitors (MKIs) are effective options in the treatment of cancer, significantly increasing the progression-free survival (PFS) of many tumors. Data about severity and prevalence of metabolic adverse events is scarce and may be significant in patients with a better survival. The aim of this study was to investigate glucose and lipids values of patients treated with lenvatinib. Secondary aims included evaluating changes in the estimated risk of cardiovascular disease and the relationship between metabolic alterations and tumor response to therapy.
Methods
A retrospective pilot study on 29 patients with advanced differentiated thyroid cancer was conducted. Clinical and biochemical characteristics were collected at the day of therapy initiation and follow up. The 10-year risk of cardiovascular disease was estimated with the SCORE2 and SCORE2-OP algorithms. Tumor burden change was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST).
Results
No differences in glucose values were observed. A significant increase in total cholesterol (208 ± 41 versus 245 ± 67 mg/dl), triglycerides (112 [interquartile range, 58–326] versus 157 [78–296] mg/dl), calculated LDL cholesterol (128 [66–204] versus 140 [81–308] mg/dl) and cardiovascular risk was observed from baseline to follow up. Furthermore, these parameters increase progressively with increasing tumor response to therapy.
Conclusions
Despite limitations, this study shows an association between the use of lenvatinib and the development of lipid alterations in patients with advanced thyroid cancer. However, further investigation is necessary for a more comprehensive understanding of the adverse metabolic profile of MKIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
- Department of Translational and Precision Medicine, Sapienza University, Rome, Italy. giorgio.grani@uniroma1.it.
ORCID-Profile: E Acitelli, M Sponziello, G Grani, C Durante, M Maranghi
Zitieren
APA
Acitelli, E., Verrienti, A., Sponziello, M., Pecce, V., Minicocci, I., Macera, M., Barp, S., Lucia, P., Grani, G., Durante, C., & Maranghi, M. (2024). Effects of lenvatinib on glucose, cholesterol, triglycerides and estimated cardiovascular risk in patients with advanced thyroid cancer. Endocrine. https://doi.org/10.1007/s12020-024-04003-y
Vancouver
Acitelli E, Verrienti A, Sponziello M, Pecce V, Minicocci I, Macera M, et al. Effects of lenvatinib on glucose, cholesterol, triglycerides and estimated cardiovascular risk in patients with advanced thyroid cancer. Endocrine. 2024. doi:10.1007/s12020-024-04003-y
BibTeX
@article{Acitelli2024,
author = {Acitelli, E and Verrienti, A and Sponziello, M and Pecce, V and Minicocci, I and Macera, M and Barp, S and Lucia, P and Grani, G and Durante, C and Maranghi, M},
title = {Effects of lenvatinib on glucose, cholesterol, triglycerides and estimated cardiovascular risk in patients with advanced thyroid cancer},
journal = {Endocrine},
year = {2024},
doi = {10.1007/s12020-024-04003-y}
}
EUVIMED